Bevacizumab and irinotecan for recurrent oligodendroglial tumors.
Taillibert S, Vincent LA, Granger B, Marie Y, Carpentier C, Guillevin R, Bellanger A, Mokhtari K, Rousseau A, Psimaras D, Dehais C, Sierra del Rio M, Meng Y, Laigle-Donadey F, Hoang-Xuan K, Sanson M, Delattre JY.
Taillibert S, et al.
Neurology. 2009 May 5;72(18):1601-6. doi: 10.1212/WNL.0b013e3181a413be.
Neurology. 2009.
PMID: 19414728